TherapeuticsMD Inc. (TXMD)

Low-dose Bijuva NDA filed, Approval is Anticipated in Q4 2020

February 4, 2020
Report ID: 11265
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


TherapeuticsMD Inc.
TherapeuticsMD Inc.
Healthcare
Drug Manufacturers
Ticker
TXMD
Current Price
$3.25 -2.4%
Market Cap
$34.4M
Price Target
Refer to Report
Volume
18.1K
52wk Range
$3.25 - $7.99
Related Research Reports
11/9/2020

Q3 EPS: Annovera Sales Impress
Q3 EPS: Annovera Sales Impress (TXMD)
7/15/2020

Expanded Patient Access of Annovera
Expanded Patient Access of Annovera (TXMD)
5/7/2020

Focusing on Annovera and Imvexxy Commercialization
Focusing on Annovera and Imvexxy Commercialization (TXMD)
3/30/2020

Not Unexpected: 2020 Guidance is Suspended
Not Unexpected: 2020 Guidance is Suspended (TXMD)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.